- Conditions
- Pulmonary Hypertension
- Interventions
- Spironolactone, Placebo
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 373
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pulmonary Hypertension
- Interventions
- bosentan, placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Torrance, California • Boston, Massachusetts + 3 more
- Conditions
- Pulmonary Arterial Hypertension, Exercise Associated Pulmonary Arterial Hypertension
- Interventions
- PET-CT Imaging with [89Zr]-bevacizumab
- Diagnostic Test
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Ambrisentan plus Spironolactone, Ambrisentan plus Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hypertension, Pulmonary
- Interventions
- sildenafil, placebo
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 15 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- MTT with antibiotic preconditioning + fiber supplementation, MTT with antibiotic preconditioning + placebo supplementation, MTT with placebo + placebo supplementation.
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- imatinib mesylate, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
- Conditions
- Idiopathic Pulmonary Arterial Hypertension, Primary Pulmonary Hypertension, Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension
- Interventions
- Diltiazem Hydrochloride, Sugar Pill
- Drug
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- AV-101
- Drug
- Lead sponsor
- Aerovate Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 12 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- UT-15C SR
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 15 Years to 80 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Tucson, Arizona • St Louis, Missouri + 3 more
- Conditions
- Pulmonary Arterial Hypertension, Right Heart Failure, Right Ventricular Dysfunction, Pulmonary Vascular Disorder
- Interventions
- Valsartan 40 mg, Placebo
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Selexipag
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 15
- States / cities
- La Jolla, California • San Francisco, California • Torrance, California + 11 more
- Conditions
- Idiopathic Pulmonary Arterial Hypertension, Cardiomyopathy
- Interventions
- Nitric Oxide for inhalation, Oxygen, Nitric Oxide plus Oxygen
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 4 Weeks to 18 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 8
- States / cities
- Stanford, California • Denver, Colorado • Boston, Massachusetts + 5 more
- Conditions
- Alveolitis, Fibrosing, Fibrosis, Pulmonary, Hypertension, Pulmonary
- Interventions
- sildenafil
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension
- Interventions
- Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device, Placebo delivered via INOpulse DS Device, Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device
- Combination Product
- Lead sponsor
- Bellerophon Pulse Technologies
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 38 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Bosentan
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 3 Months to 12 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • New York, New York
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Sotatercept, Placebo
- Drug · Other
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orange, California + 22 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Treprostinil
- Drug
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 3
- States / cities
- Tucson, Arizona • San Francisco, California • Torrance, California
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension
- Interventions
- 15 mg sodium nitrite inhalation solution, 90 mg sodium nitrite inhalation solution, 45 mg sodium nitrite inhalation solution, 120 mg sodium nitrite inhalation solution, 25% MTD sodium nitrite inhalation solution
- Drug
- Lead sponsor
- Aires Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 56 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Macitentan
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 32 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Selexipag, Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 43
- States / cities
- Mobile, Alabama • Tucson, Arizona • La Jolla, California + 32 more
- Conditions
- Systemic Sclerosis, Scleroderma, Pulmonary Hypertension, Pulmonary Arterial Hypertension
- Interventions
- Not listed
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 602 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 25
- States / cities
- Los Angeles, California • Stanford, California • Denver, Colorado + 18 more
- Conditions
- Pulmonary Hypertension
- Interventions
- Inhaled treprostinil, Placebo inhalation solution
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 12 more